FDA grants approval to Axsome Therapeutics’ migraine medication containing Betadex Sulfobutylether Sodium
The U.S. Food and Drug Administration has approved Axsome Therapeutics’ new migraine treatment tablet on 30 January 2025 [1]. Marketed
Tag: SBECD
Repurposing doxycycline for Alzheimer’s treatment: Challenges from a nano-based drug delivery perspective
Drug repurposing, also known as drug repositioning, involves identifying new applications for drugs whose effects in a disease are already
A review on application of sodium sulfobutylether-β-cyclodextrin
According to the authors of this review paper, SBE-β-CD finds widespread application in pharmaceutics as a protective agent and pKa regulator,
Axsome Therapeutics’ betadex sulfobutylether sodium containing composition: FDA Acceptance of NDA Resubmission
Axsome Therapeutics, Inc., an U.S.-based biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS)
Meloxicam potassium containing nasal powders based on charged β-cyclodextrin
Nasal drug delivery is increasingly recognized as an alternative to oral and parenteral administration, offering advantages such as rapid absorption
Ipecon®: a novel betadex sulfobutylether sodium containing veterinary drug composition
A Russian startup company, Vetstem, located at Skolkovo, Moscow successfully markets an antiviral composition for the treatment of feline infectious
Rutin/Sulfobutylether-β-Cyclodextrin as a Promising Therapeutic Formulation for Ocular Infection
Ocular pathologies present significant challenges to achieving effective therapeutic results due to various anatomical and physiological barriers. Natural products such
A Novel In Situ Gelling System of Quercetin/Sulfobutyl-Ether-β-Cyclodextrin Complex-Loaded Chitosan Nanoparticles for the Treatment of Vulvovaginitis
Vulvovaginitis is a growing concern worldwide because of increasing drug resistance, drug toxicity, low bioavailability, and limitations of topical administration.
Veklury is the first approved antiviral agent now for extended pediatric use and for those patients who are suffering in all stages of renal disease
Veklury, a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor, was approved by FDA for the treatment COVID-19 in adults and pediatric
Dual function of sulfobutylether-betadex in antiviral Veklury®: a remdesivir solubilizer and an effector
A recent publication written by a team of University of Debrecen reported that the excipient, sulfobutylether-betadex (SBECD), in Veklury® (remdesivir